RECOMBINATE 500 IU

Nazione: Israele

Lingua: inglese

Fonte: Ministry of Health

Principio attivo:

COAGULATION FACTOR VIII RECOMBINANT 500 IU/VIAL

Commercializzato da:

TEVA MEDICAL MARKETING LTD.

Codice ATC:

B02BD05

Forma farmaceutica:

POWDER FOR SOLUTION FOR INJECTION

Via di somministrazione:

I.V

Prodotto da:

BAXTER S.A., BELGIUM

Gruppo terapeutico:

COAGULATION FACTOR VII

Indicazioni terapeutiche:

The use of Recombinate is indicated in the treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency). Recombinate is also indicated in the perioperative management of patients with haemophilia A. Recombinate is appropriate for use in children of all ages including the newborn. (Safety and efficacy studies have been performed in both previously treated and previously untreated children). The product in not suitable for the treatment of von Willebrand's disease.

Data dell'autorizzazione:

2010-07-01